CMS reports it has blocked more than $1.6 billion in questionable Medicare laboratory payments and ramped up tech-driven enforcement under the current administration.

The Centers for Medicare & Medicaid Services says it has halted over $1.6 billion in potentially improper laboratory payments since the start of the Trump Administration, crediting sharper oversight and new tools. That total reflects a mix of revocations, suspensions, recoupments, and referrals tied to lab billing abuses. The agency frames this as part of a broader push to restore integrity and protect the Medicare Trust Fund.

The agency’s reported enforcement totals break down into several concrete categories, showing where those dollars came from and how they were stopped. These moves targeted both phantom operations and suspect billing schemes that pushed claims through the system. The numbers provide a clear snapshot of a crackdown aimed at labs that lacked legitimate operations or billing practices.

• $732 million in savings from the revocation of 157 providers enrolled in Medicare;
• Over $500 million in potentially fraudulent payments halted through 185 payment suspensions following investigations of 600 labs;
• $276 million recouped from 442 identified overpayments previously issued to suspect labs;
• $127 million in potentially fraudulent payments prevented after 85 law enforcement referrals from a CMS contractor.

“When laboratories bill Medicare for tests they never performed, it drains the Medicare Trust Fund and diverts resources away from beneficiaries who need them,” said CMS Administrator Dr. Mehmet Oz. “That’s why, under the leadership of the White House Anti-Fraud Task Force, CMS has built a technology-powered fraud prevention operation to root out scammers all across our health care system, from laboratory testing and hospice care to medical equipment and autism therapy. We won’t stop until we’ve restored program integrity and ensured that fraudsters have nowhere left to hide.”

CMS credits advanced analytics, including artificial intelligence and machine learning, for spotting unusual billing patterns that human reviewers might miss. These tools learn what normal lab activity looks like, then flag odd mixes of tests, billing, documentation, and provider relationships. When a pattern triggers concern, claims can be flagged for review, held, rejected, or denied before Medicaid funds are released.

The agency says it has honed in on specific lab fraud tactics that drain resources and hurt patients. Common red flags include billing for medically unnecessary tests on beneficiaries with no relationship to the ordering provider, claims for services not rendered, and up-coded services. Fraudulent activity can touch pathogen detection, high-complexity drug testing, and genetic testing, among other areas.

CMS supplied several case examples to illustrate how these enforcement tools work in practice and what they uncovered. Those examples show both blatant schemes and attempts to game the controls once detected. In each case, the agency combined data analysis with payment suspensions, recoupment, and provider revocation when warranted.

• An owner of a consulting operation enrolled 14 labs and billed more than $24 million for services that could not have been rendered because none of the labs were operational; CMS suspensions are holding $12 million, it has recouped $7 million, and 11 of the 14 enrollments were revoked while investigations continue for the rest.
• A Texas lab that began billing in February 2026 was denied $1.2 million in claims after CMS detected suspicious activity; a later attempt to change billing practices triggered further monitoring and a suspension that stopped more than $150,000 in suspect payments before the provider was revoked.
• A second Texas lab that ramped up billing in May 2026 had $1.9 million in claims denied and an additional $1.7 million captured by a payment suspension; that provider is currently under review for revocation.

The agency points to a much larger trend of tightened enforcement beyond these lab cases, saying Medicare fraud prevention efforts under the administration produced a record $42 billion in savings in Fiscal Year 2025. For 2026 so far, CMS reports identifying $1.8 billion in Medicare overpayments through medical review, collecting $378 million via post-payment reviews, and suspending more than $539 million in suspected fraudulent payments.

Since the start of 2026, the CMS Fraud Defense Operations Center has flagged hundreds of providers and suppliers and accounted for more than $371 million in suspended payments tied to 267 entities. The agency highlights major categories in those suspensions, including suspect durable medical equipment billing, skin substitute claims, and hospice providers as primary areas of concern.

• More than $226 million tied to suspect durable medical equipment billing;
• More than $53 million linked to suspect skin substitute billing;
• More than $23 million associated with suspect hospice providers.

These enforcement actions show an active approach to protecting Medicare dollars by combining data science, payment controls, and coordinated law enforcement referrals. Investigations, suspensions, and revocations remain in motion, and CMS says it will continue to use automated analytics alongside traditional oversight to stop abusive billing before it harms beneficiaries or the Trust Fund.